What is ZURA's current stock price?

ZURA (Zura Bio Limited) is currently trading at $4.36 with a market cap of $283.5M.

What sector is Zura Bio Limited in?

Zura Bio Limited (ZURA) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ZURA a good stock to buy?

Analysts have a Buy consensus on ZURA with a price target of $15.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ZURA Zura Bio Limited

Healthcare

$4.36-1.80%ClosedMarket Cap: $283.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.26

P/S

0.00

EV/EBITDA

-0.71

DCF Value

$1.16

FCF Yield

-25.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-54.6%

ROA

-33.0%

ROIC

-37.6%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-24.2M	$—
Q4 null	$0.00	$-17.2M	$—
FY null	$0.00	$-68.7M	$—
Q3 null	$0.00	$-18.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$15.00

Target (Median)

$15.00

Target Range

$15.00 - $15.00

1 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

Chardan CapitalBuy

2026-03-23

OppenheimerOutperform

2026-03-20

Chardan CapitalBuy

2025-11-14

Chardan CapitalBuy

2025-09-30

HC Wainwright & Co.Neutral

2025-08-19

Trading Activity

Insider Trades

View All

Whale Garyofficer: Chief Technology Officer

SellThu Apr 02

Nistala Kiranofficer: See Remarks

SellThu Apr 02

Kulkarni Sandeep Chidambardirector, officer: Chief Executive Officer

SellThu Apr 02

Hyllengren Eric Jofficer: Chief Financial Officer

SellThu Apr 02

Davis Kimofficer: Chief Legal Officer

SellThu Apr 02

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.09

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

Peers